ITS management has a strong track record in vaccine development.

Carlton Brown: Chief Executive Officer

Carlton is a veterinarian and holds an MBA from The London Business School. He has a commercial background in life sciences; strategic marketing (SmithKline Beecham), corporate and business development (Cortecs Plc) and global healthcare investment banking (Dresdner Kleinwort Wasserstein). Prior to ITS, he was Commercial Director and Chief Operating Officer of a French vaccine company. In October 2003 Carlton co-founded ITS and since then has successfully raised the Company’s Seed, Series-A funding rounds and grant funding. He strategically directed the innovation and development of the vaccine platforms from inception to permit the targeting of mutating viruses whilst addressing key vaccine development imperatives. Carlton is particularly interested in developing products capable of addressing key market needs with a specific focus on market disruption.

Jill Makin: Head of Vaccine Manufacture and Controls (Consultant; PTE)

Jill has worked in biopharmaceutical development for 20 years, for Emergent Biosolutions (as Vice President, R&D), Microscience Ltd (as R&D Director), Celltech-Medeva (in a number of roles) and Evans Vaccines (where she completed a PhD, part-time, in vaccine research). During this time she has developed an in-depth knowledge of vaccine development and held positions of responsibility in each of the functional areas of R&D, including manufacturing and testing, pre-clinical development, regulatory affairs and clinical development. She has extensive project management experience of Phase I, II and III, including management of a vaccine through the centralised European approval system. Jill now works for Immune Targeting Systems, on a consultancy basis, with responsibility for chemistry, manufacturing and controls (CMC).

Bertrand Georges, PhD: Chief Scientific Officer

Bertrand is a co-founder and a molecular and vaccine immunologist with a key expertise in the rational design of synthetic peptide based vaccines. Bertrand was a driving force behind the development of the Company’s vaccine technologies. He co-invented the ITS bioinformatics platform which led to the design of novel vaccines for Influenza-A, Human Immunosuppressive Virus (HIV), Hepatitis-C and Feline Immunosuppressive Virus FIV. Prior to ITS, he invented numerous T-cell epitope identification platforms (in silico, in vitro, in vivo). Bertrand is responsible for driving the Company’s scientific program including immunology and vaccine formulation and works closely with the CEO to drive product development.